Mentions of brand or product names are for identification only and do not constitute endorsement.
You can find more information at Peptidesaurora.
Semax is a synthetic peptide derived from adrenocorticotropic hormone (ACTH). It has been studied for cognitive effects in animals and limited human trials. This article examines whether Semax nasal spray could address cognitive fatigue reported after oral semaglutide use. The focus is on mechanisms beyond brain-derived neurotrophic factor (BDNF).
Oral semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is approved for type 2 diabetes and weight management. Some users report mental tiredness, reduced motivation, or slower thinking during treatment. The cause is unclear. GLP-1 receptors exist in brain regions tied to cognition and reward. Reduced food intake and glucose changes may also play a role.
Semax has a different profile. It was developed in Russia and is used there for stroke, cognitive impairment, and optic nerve disease. A 2018 review in Frontiers in Pharmacology summarized its neuroprotective and nootropic effects. The peptide increases BDNF and nerve growth factor (NGF) in some models. But its actions go beyond neurotrophins.
This article reviews published research on Semax and related peptides. It then discusses how those mechanisms might relate to GLP-1 related cognitive fatigue. No human trial has directly tested Semax for this specific problem. The analysis is therefore inferential.
What Is Semax and How Does It Work?
Semax is a heptapeptide: Met-Glu-His-Phe-Pro-Gly-Pro. It is a fragment of ACTH (4-10) with a Pro-Gly-Pro tail added. This tail increases stability and changes receptor interactions. Semax binds to melanocortin receptors, especially MC4R and MC5R. It also influences dopamine and serotonin systems.
In animal studies, Semax improved learning and memory. A 2019 study in Neuroscience and Behavioral Physiology found that Semax increased BDNF mRNA in rat hippocampus. But the same study noted changes in other genes. These included genes for synaptic plasticity and inflammation. So BDNF is not the whole story.
Semax also affects the expression of genes involved in neuroprotection. It reduces oxidative stress markers. It modulates the immune response in the brain. These effects may be relevant to cognitive fatigue. Fatigue often involves neuroinflammation and mitochondrial dysfunction.
Semax is typically given as a nasal spray. The intranasal route allows direct delivery to the brain along olfactory and trigeminal nerves. This bypasses the blood-brain barrier to some degree. A 2020 review in Biomolecules described intranasal peptide delivery for central nervous system disorders. Semax is one of the most studied examples.
P21: A Related Peptide with Different Targets
P21 is another synthetic peptide. It is derived from ciliary neurotrophic factor (CNTF). P21 was designed to mimic the cognitive effects of CNTF without its side effects. A 2021 study in Behavioural Brain Research showed P21 improved memory in mice. It did so by increasing neurogenesis in the hippocampus.
P21 and Semax are often compared. Both raise BDNF. But P21 has stronger effects on neurogenesis. Semax has broader effects on neurotransmitter systems. A comparison of P21 and Semax for GLP-1-induced cognitive slowing discusses these differences in detail.
For post-oral semaglutide fatigue, P21 might help with motivation and learning. Semax might help more with attention and mental energy. The choice depends on the specific symptoms. Neither has been tested in humans for this indication.
Selank: Anxiolytic Peptide with Cognitive Effects
Selank is another Russian peptide. It is a synthetic analogue of tuftsin. It has anxiolytic and nootropic properties. Selank increases BDNF in some brain regions. It also modulates the expression of genes related to GABA and serotonin.
Selank is often used for anxiety and stress. Cognitive fatigue from semaglutide may be worsened by stress or low mood. Selank could address that component. But it is less directly nootropic than Semax. A 2017 study in Neuroscience Letters found Selank improved memory in rats under stress. The effect was linked to changes in hippocampal neurochemistry.
Selank is not the focus here. But it is relevant because it shares some mechanisms with Semax. Both affect BDNF and neuroinflammation. Selank has a stronger anxiolytic profile.
Dihexa: A Small Molecule with Potent Nootropic Effects
Dihexa is not a peptide. It is a small molecule that activates hepatocyte growth factor (HGF). HGF is a neurotrophic factor. Dihexa increased synaptogenesis in animal models. A 2012 study in Journal of Pharmacology and Experimental Therapeutics showed Dihexa improved cognitive function in rats. The effect was larger than BDNF alone.
Dihexa is often mentioned alongside Semax and P21. It has a different mechanism. It does not directly raise BDNF. Instead, it enhances synaptic connections. This could be useful for cognitive fatigue. But Dihexa has less human safety data than Semax.
For post-oral semaglutide fatigue, Dihexa might be considered if BDNF pathways are not the main issue. But the lack of human trials is a concern.
MOTS-c and NAD+: Metabolic Peptides
MOTS-c is a mitochondrial-derived peptide. It improves metabolic flexibility and insulin sensitivity. A 2015 study in Cell Metabolism showed MOTS-c reversed age-related insulin resistance in mice. It also improved physical performance.
NAD+ is a coenzyme involved in cellular energy production. NAD+ levels decline with age and metabolic stress. Nicotinamide riboside and NMN are precursors that raise NAD+. They have been studied for fatigue and cognitive decline.
These compounds are relevant because semaglutide changes energy metabolism. Some cognitive fatigue may stem from reduced glucose availability or mitochondrial function. MOTS-c and NAD+ precursors could address that. But they are not directly nootropic like Semax.
Semax does not directly raise NAD+ or act on mitochondria. Its effects are more on neuroplasticity and neurotransmitter balance. So the mechanisms are complementary, not overlapping.
Mechanisms Beyond BDNF
BDNF is often cited as the key mediator of Semax's cognitive effects. But the evidence suggests a broader picture. Semax changes the expression of dozens of genes. It affects dopamine D2 receptors, serotonin 5-HT2A receptors, and glutamate transporters.
A 2016 study in Doklady Biochemistry and Biophysics found that Semax altered the expression of genes involved in synaptic vesicle cycling. This is a process essential for neurotransmitter release. Impaired vesicle cycling can cause mental fatigue.
Semax also reduces neuroinflammation. It lowers levels of pro-inflammatory cytokines in the brain. Neuroinflammation is a known cause of fatigue in many conditions. GLP-1 receptor agonists may reduce peripheral inflammation. But their effects on brain inflammation are less clear.
Another mechanism is modulation of the hypothalamic-pituitary-adrenal (HPA) axis. Semax is an ACTH fragment. It can influence cortisol and stress responses. Chronic stress or HPA dysregulation can cause fatigue. Semax may normalize this axis.
Finally, Semax increases cerebral blood flow. A 2014 study in Bulletin of Experimental Biology and Medicine showed Semax improved microcirculation in rat brain. Reduced blood flow can cause mental tiredness. This effect is independent of BDNF.
Why Oral Semaglutide Might Cause Cognitive Fatigue
Oral semaglutide lowers blood glucose and body weight. It also slows gastric emptying. These changes can affect brain function. The brain relies on a steady supply of glucose. Rapid reductions in blood glucose can cause mental fatigue.
GLP-1 receptors are found in the hypothalamus, hippocampus, and brainstem. Activation of these receptors can alter appetite and reward. Some users report reduced interest in food and other activities. This anhedonia may be perceived as cognitive fatigue.
Semaglutide also reduces inflammation and oxidative stress. This is generally beneficial. But the initial adaptation period may cause transient symptoms. Nausea, reduced calorie intake, and sleep changes can all contribute to mental tiredness.
There is no published study on Semax for semaglutide-related cognitive fatigue. The connection is theoretical. But the mechanisms of Semax align with several possible causes. It increases BDNF, reduces neuroinflammation, improves blood flow, and modulates neurotransmitters.
P21 for cognitive fog during GLP-1 dose titration explores a related peptide for a similar problem. That article discusses how P21's neurogenic effects might help during dose increases.
What Does the Research Say About Semax in Humans?
Semax has been used in Russia for decades. Human studies are mostly small and uncontrolled. A 2010 trial in Zhurnal Nevrologii i Psikhiatrii tested Semax in patients with chronic cerebral ischemia. It improved cognitive function and reduced fatigue. But the study had no placebo group.
A 2018 pilot study in Human Physiology examined Semax in healthy volunteers. It found improved attention and working memory after a single intranasal dose. The effect was modest. No serious adverse events were reported.
These studies suggest Semax is well tolerated. But they do not prove efficacy for semaglutide-related fatigue. The populations and conditions are different.
Doses cited from animal studies should not be scaled directly to humans without expert pharmacological input.
Annotated Critique of Key Studies
The 2019 study by Medvedeva et al. in Neuroscience and Behavioral Physiology is often cited for Semax and BDNF. It used rats and measured mRNA after repeated Semax injections. The study found increased BDNF in the hippocampus. But it also found changes in other neurotrophins. The sample size was small (n=8 per group). The route of administration was intraperitoneal, not intranasal. So the relevance to nasal spray in humans is uncertain.
The 2018 review by Kolomin et al. in Frontiers in Pharmacology is a good overview of Semax mechanisms. It summarizes gene expression data from multiple studies. It concludes that Semax has pleiotropic effects. But the review is based mostly on animal and in vitro work. Human data are sparse.
The 2010 clinical trial in Russia had methodological weaknesses. It was open-label. The outcome measures were not standardized. The patient population had vascular cognitive impairment, not drug-induced fatigue. So extrapolation is risky.
A 2022 review in Peptides examined intranasal peptide delivery. It noted that Semax has good bioavailability via the nasal route. But it also warned that nasal inflammation or congestion can reduce absorption. This is relevant for users with allergies or colds.
Implications and Limits
Semax is a promising candidate for cognitive enhancement. Its mechanisms go beyond BDNF. It affects neuroinflammation, blood flow, and neurotransmitter systems. These actions could theoretically help with post-oral semaglutide cognitive fatigue.
But there are major gaps. No human trial has tested Semax for this indication. The existing human studies are small and uncontrolled. The long-term safety of intranasal Semax is not well documented. The optimal dose and frequency are unknown.
Other peptides like P21, Selank, and Dihexa have different profiles. They might be more or less suitable depending on the individual. P21 for GLP-1-induced anhedonia discusses a related symptom. Semax vs P21 for focus and anxiety compares the two peptides directly.
MOTS-c and NAD+ precursors address metabolic fatigue. They might be combined with Semax in theory. But no studies have tested such combinations. The risk of interactions is unknown.
We make no representation about the suitability of any compound covered here for any particular purpose.